- Joined
- 28 May 2020
- Posts
- 6,255
- Reactions
- 11,851
The Australian sees CSL going to $300 based on a ridiculously expensive drug for the treatment of Haemophilia.
Mick
Lets hope it works for the sufferers of haemophilia.A patient in the US has become the first person to receive the world’s most expensive drug, Hemgenix, as CSL begins to commercialise its treatment for haemophilia B.
At $3.5m a shot, Hemgenix aims to effectively cure patients in one dose, replacing regular infusions that can cost more than $20m over an adult lifetime.
Analysts had been anticipating a quicker launch of the drug, which the US Food and Drug Administration approved last November, and initially expected that it would send CSL shares soaring above $300 again.
Part of the reason why commercialisation has been slower than expected is that health funds have been reviewing coverage of Hemgenix on a case-by-case basis.
But CSL has confirmed that more than 60 per cent of the US population has health policies covering the cost of the one-time only gene therapy.
An Australian launch is understood to be several years away, with the drug currently before the Therapeutics Goods Administration.
CSL Behring vice president for North America, Bob Lojewski, highlighted the cost savings to the health system, despite the high upfront price.
“Discussions between CSL Behring and the payer community on the value proposition offered for Hemgenix have been positive, which is reflected in the policies that have been written,” Mr Lojewski said.
“As part of our longtime promise to patients, CSL Behring is thrilled to mark this latest milestone of the first commercial patient having received Hemgenix and look forward to continuing to deliver this paradigm-shifting treatment to the haemophilia B community.”
Haematologist Matthew Ryan administered the first dose of the drug to patient in Wisconsin and said it was a “long-awaited advancement” for people with haemophilia B – a debilitating illness that plagued European royalty in the 19th and early 20th centuries and affects about one in 40,000 males today.
Mick